#immunotherapy #AlligatorBioscience #mitazalimab #mFOLFIRINOX #pancreaticcancer #metastaticpancreaticadenocarcinomacancer #mPDAC #mPDACpatients #OPTIMIZE1trial #metastaticpancreaticcancertreatment #healthoutcomesresearch #ASCOGastrointestinalCancersSymposium
pharmatimes.com/news/alligat...
pharmatimes.com/news/alligat...
Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX - PharmaTimes
Comparison shows improved survival rates for pancreatic cancer treatment
pharmatimes.com
January 31, 2025 at 11:34 AM